Ayala Pharmaceuticals, a publicly-traded clinical-stage oncology company, agreed to merge with Biosight, a privately-held pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders. Financial terms were not disclosed “The addition of Biosight’s lead asset aspacytarabine (BST-236) fits with our strategic vision and core competencies and provides us with additional avenues towards key clinical catalysts. Along with the merger, we have plans to strengthen our balance sheet and execute our clinical plans, with the goal of creating sustainable value for patients and shareholders,” Ken Berlin, Ayala President and CEO.